Gilead Positioned To Benefit From Potential HIV Guidelines Change
This article was originally published in The Pink Sheet Daily
Executive Summary
Emerging data on initiating anti-retroviral treatment earlier in HIV patients could broaden the treatment-naïve market.
You may also be interested in...
Merck's Isentress Approved for All Adult HIV Patients
Isentress in combination therapy has less effect on lipid levels than standard of care Sustiva-based therapy in HIV treatment naïve patients, study shows.
Merck's Isentress Approved for All Adult HIV Patients
Isentress in combination therapy has less effect on lipid levels than standard of care Sustiva-based therapy in HIV treatment naïve patients, study shows.
Gilead President Thinks Firm Is Safe From Pfizer/GSK HIV Joint Venture - For Now
Near term, Gilead’s Milligan doesn’t see “anything really competitive.”